+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Overactive Bladder Treatment Market 2019-2025

  • ID: 5129629
  • Report
  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan plc
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Endo International plc
  • Lupin Ltd.
  • Mylan N.V.
  • MORE
Global Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Therapy (Anticholinergics, Intravesical Instillation, Mirabegron, Neurostimulation, and Others), By Application (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder) and Forecast, 2019-2025.

The global overactive bladder treatment market is estimated to witness moderate growth during the forecast period. The increasing ageing population is the major factor in driving the market growth. As per the United Nations, in 2019, 703 million people were aged 65 and over globally. In 2050, the number of older persons is anticipated to double to 1.5 billion. The share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. The risk of developing conditions including Parkinson’s disease and urinary incontinence increases with age. Urinary incontinence is common in the elderly population, particularly in women.

Structural changes occur with the age in the bladder and urethra that may lead to the development of urinary incontinence. This, in turn, contributes to the demand for overactive bladder treatment in which the bladder is not able to normally hold urine. Anticholinergics medications are used to control the symptoms of overactive bladder and urge incontinence. These medications can reduce the possibility of leakage and can be used in combination with behavioral therapies to ease the symptoms of overactive bladder.

Geographically, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and Rest of the world (RoW). In 2018, North America is anticipated to hold a significant share in the market owing to the increasing demand for neurostimulation therapy and the increasing prevalence of Parkinson’s disease and urinary incontinence in the region. Asia-Pacific is estimated to witness potential growth during the forecast period owing to the significant rise in the ageing population and urinary-associated disorders in the region. The rising shift towards Indian pharmaceutical companies, including Cipla and Glenmark Pharmaceuticals Ltd. towards the development of medicines for overactive bladder treatment is further anticipated to drive the market growth in the region.

Some crucial players in the market include Astellas Pharma Inc., Pfizer Inc., Medtronic plc, Allergan plc, and Mylan N.V. Product launches are considered as a key strategy adopted by the market players to expand market share. For instance, in April 2019, Teva Pharmaceutical Industries Ltd. declared the introduction of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the US. These are a muscarinic antagonist indicated to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This new launch will support the company to increase its market share in the US.

Research Methodology

The market study of the global overactive bladder treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Overactive Bladder Treatment Market Research and Analysis by Therapy
2. Global Overactive Bladder Treatment Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the global overactive bladder treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global overactive bladder treatment market.
  • Insights about market determinants, which are stimulating the global overactive bladder treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan plc
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Endo International plc
  • Lupin Ltd.
  • Mylan N.V.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Astellas Pharma Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Medtronic plc
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Allergan plc
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Mylan N.V.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Overactive Bladder Treatment Market by Therapy
5.1.1. Anticholinergics
5.1.1.1. Solifenacin
5.1.1.2. Darifenacin
5.1.1.3. Oxybutynin
5.1.1.4. Trospium
5.1.1.5. Tolterodine
5.1.1.6. Fesoterodine
5.1.1.7. Others
5.1.2. Intravesical Instillation
5.1.3. Mirabegron
5.1.4. Neurostimulation
5.1.5. Others
5.2. Global Overactive Bladder Treatment Market by Application
5.2.1. Neurogenic Overactive Bladder
5.2.1.1. Parkinson’s Disease
5.2.1.2. Stroke
5.2.1.3. Multiple Sclerosis
5.2.1.4. Spinal Cord Injury
5.2.1.5. Others
5.2.2. Idiopathic Overactive Bladder

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Alembic Pharmaceuticals Ltd.
7.2. Allergan plc
7.3. Apotex Inc.
7.4. Astellas Pharma Inc.
7.5. Axonics Modulation Technologies, Inc.
7.6. BlueWind Medical
7.7. Cadila Healthcare Ltd.
7.8. Cipla Ltd.
7.9. Endo International plc
7.10. Glenmark Pharmaceuticals Ltd.
7.11. Hisamitsu Pharmaceutical Co., Inc.
7.12. Intas Pharmaceuticals Ltd.
7.13. Johnson & Johnson Services, Inc.
7.14. Laborie, Inc.
7.15. Lupin Ltd.
7.16. Macleods Pharmaceuticals Ltd.
7.17. Medtronic plc
7.18. Mylan N.V.
7.19. Pfizer Inc.
7.20. Sanofi S.A.
7.21. Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • Alembic Pharmaceuticals Ltd.
  • Allergan plc
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Axonics Modulation Technologies, Inc.
  • BlueWind Medical
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Endo International plc
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • Laborie, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Medtronic plc
  • Mylan N.V.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll